AstraZeneca has pledged approximately £650 million to increase its presence in the UK, including a new R&D facility and the expansion of its vaccine manufacturing capabilities.

According to the UK government, around $573 million (£450 million) of AstraZeneca’s commitment will be used to construct a new facility for the research, development and manufacture of vaccines in Speke, Liverpool. Source: Biospace 7/3/2024